Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study.
The epidemiology and pathophysiology of cancer-associated bone disease was reviewed in a new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group.
A review of calcium and vitamin D supplementation trials revealed that current recommended doses are inadequate to prevent bone mineral density loss in women undergoing breast cancer therapy.
FDA-related news items of relevance from the month of June, 2013.
When patients with giant-cell tumor of the bone were treated with denosumab, which is a drug targeted against a protein that promotes bone destruction, the number of tumor giant cells decreased and new bone formation increased.
Calcium and/or vitamin D supplementation at commonly recommended doses does not prevent bone loss from androgen-deprivation therapy.
Denosumab better prevents skeletal complications, ups health-related QoL versus zoledronic acid.
A history of periodontitis may be associated with an increased risk of HPV-positive tumors in persons with head and neck squamous cell carcinoma.
Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer.
The risk of bone loss resulting from breast and prostate cancer treatment has been highlighted by researchers in Canada.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|